Diabetic Ketoacidosis and Persistent Hyperglycemia as Long-term Complications of L-asparaginase-induced Pancreatitis

Yu-Juei Hsu  
Yeu-Chin Chen  
Ching-Liang Ho  
Woei-Yau Kao  
Tsu-Yi Chao

Division of Hematology/Oncology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, R.O.C.

Key Words
asparaginase;  
diabetic ketoacidosis;  
hyperglycemia;  
pancreatitis

Diabetic ketoacidosis (DKA) and pancreatic pseudocysts are rare complications following treatment of hematological malignancies with L-asparaginase (L-asp). Persistent hyperglycemia with recurrent DKA presenting as a long-term complication of L-asp-induced pancreatitis is even rarer. A 21-year-old man with pre-B-type acute lymphoblastic leukemia (ALL) developed pancreatic pseudocysts, DKA and persistent hyperglycemia after L-asp therapy. The patient was treated with oral hypoglycemic agents (OHA) for sugar control thereafter. Ten months later, another episode of DKA developed during relapsed ALL with out having obvious precipitating factors. Insulin was then instituted for control of his blood sugar until death. The leukemic process may play some role in glucose homeostasis and may be considered as a precipitating factor for DKA. The patient finally died of disease progression of ALL and sepsis 2 years after the initial diagnosis of ALL.

Case Report

A 21-year-old man sought medical attention for persistent fever in January 1999 and was diagnosed to have ALL of pre-B cell type. He had no family history of diabetes mellitus or other endocrinological disorders. Complete remission (CR) was achieved after induction therapy with vincristine, daunomycin and prednisolone. Additionally, CNS prophylaxis with intrathecal methotrexate (MTX) and cranial irradiation were instituted. After intrathecal MTX therapy, treatment with Escherichia Coli-derived L-asp (Leunase) at a dose of 18,000 IU intramuscularly every other day was given. One day after the 8th dose of L-asp, the patient complained of nausea, vomiting and...
epigastric discomfort. Physical examination showed decreased bowel sounds and local tenderness over the epigastric region with rebound tenderness. Pertinent laboratory findings showed an amylase level of 363 U/L (normal range: 30-110 U/L), a lipase level of 1,199 U/L (normal range: 23-300 U/L) and a triglyceride at 97 mg/dL (normal range: 35-150 mg/dL). Abdominal computed tomography (CT) scan demonstrated an enlarged pancreas with irregular surface and focal fluid accumulation over the para-pancreatic region (Fig. 1). The patient was treated with supportive measures for L-asp-induced pancreatitis for 2 weeks and his condition improved. He then received consolidation therapy with prednisolone, vincristine, methotrexate, and mercaptopurine. Unfortunately, he developed shortness of breath and abdominal pain 1 month later. Arterial blood gas analysis showed a pH of 6.994, a PCO$_2$ level of 23.5 mmHg, HCO$_3^-$ at 5.6 mmol/L, and a base deficit of -24.4 mmol/L. Blood glucose was 764 mg/dL and serum ketone body was 3+. Concurrent serum amylase was 167 U/L (normal range: 30-110 U/L). An abdominal CT scan showed pancreatitis with a pseudocyst forming over the tail area, about $6 \times 3$ cm$^2$ in size (Fig. 2). DKA was impressed. The patient was then treated aggressively for DKA and pancreatic pseudocyst formation, and his clinical condition improved following rehydration, parenteral nutrition, nasogastric decompression, intravenous insulin, bicarbonate supplementation and empiric antibiotics. The pancreatic pseudocyst resolved gradually, and abdominal ultrasonography revealed normal appearance of the pancreas 16 days later. Random blood glucose still fluctuated between 200 mg/dL and 300 mg/dL. Oral hypoglycemic agents were administered. During the subsequent months, he refused any further maintenance therapy. Ten months after the last dose of L-asp, his ALL relapsed and he was found to have another episode of hyperglycemic ketoacidosis. He then received treatment for his
hyperglycemic ketoacidosis and ALL again with mitoxantrone and cytosine arabinoside (Fig. 3). Although the clinical condition improved and his ALL was in second complete remission, the hyperglycemia persisted and insulin injection was needed for blood sugar control. Unfortunately, his ALL relapsed in his CNS and bone marrow in November, 2000, and he died of septic shock 2 years after the diagnosis of ALL. The clinical course of his ALL and blood glucose level are delineated in Fig. 3.

**Discussion**

Hyperglycemia is a well-documented complication of L-asp therapy for ALL. The reported incidence of hyperglycemia ranges from 2.5-23% and episodes usually resolve within an average age of 12 days. The symptoms vary from mild glucose intolerance to severe or even fatal DKA. Acute pancreatitis, which occurs in 2-16% of cases, is an other serious side effect of L-asp treatment. L-asp-related life-threatening pancreatitis, some times with the development of pseudocysts and death, have repeatedly been reported in the medical literature.

We reviewed the English medical literature and were able to identify 12 cases (including the present case) of DKA related to L-asp therapy (Table 1). A number of pathogenic mechanisms of L-asp-related hyperglycemia have been proposed, such as inhibition of insulin biosynthesis, impaired insulin secretion, a reduction in insulin receptors, and concurrent hyperglucagonemia and pancreatic islet cell damage. All reported cases of hyperglycemia and DKA after L-asp therapy were reversible and transient except 2, in which the present one. One case with persistent diabetes and ketoacidosis was reported, but that case died 6 weeks after L-asp therapy.

There is no conclusive study about the duration of the diabetogenic effect of L-asp. In the present case, persistent hyperglycemia, recurrent DKA and relapsed ALL developed 10 months after the last dose of L-asp. The pathogenesis of this long-term complication may be permanent damage of beta cells due to pancreatic pseudocysts. Such late DKA had never been reported in the literature because almost every leukemia patient suffering from severe L-asp-induced pancreatitis died before such long-term complications would appear.

DKA is a potentially fatal complication, and its management should include volume replacement, electrolyte supplementation and intravenous insulin. Early recognition of risk factors and precipitating factors for L-asp-related DKA is important. In our review, 8 of 12 patients who developed DKA after L-asp might have had precipitating factors such as acute pancreatitis, pancreatic pseudocysts, and infections in addition to the diabetogenic effect of L-asp itself. Dacou-Voutetakis et al. also suggested that leukemic process itself, through mechanisms as yet unidentified, could impair glucose metabolism. This suggestion may explain why our case developed DKA during relapsed ALL with out having obvious precipitating factors. Furthermore, some in vivo studies found that over 10 years of age, obesity, Down syndrome, family history of diabetes mellitus and high initial leukocyte count might predispose hyperglycemia in those patients who received L-asp.

Recently, 2 other preparations of asparaginase became available: (1) *Erwinia carotovora*-derived L-asp; and (2) polyethylene glycol-L-asp. Several investigators suggested that these 2 agents have fewer side effects and fewer hypersensitivity reactions. Ridgway et al. reported that asparaginase-induced hyperglycemia would be attenuated after subcutaneous injection of the *Erwinia* L-asp for *E. coli* L-asp. How ever, more studies of pharmacokinetics, toxicity, dose modification, drug interaction and protocol design are needed.

In conclusion, L-asp-induced pancreatitis could lead to long-term impairment of pancreatic function, such as DKA and persistent hyperglycemia, if patients live long enough. Postprandial blood glucose, urinary glucose, urinary ketone body and serum pancreatic enzymes should be closely monitored after L-asp therapy. Early recognition of the precipitating factors for DKA is important to prevent L-asp-related fatal complications, and the leukemic process itself may be considered as one of the predisposing factors.
Table 1. Summary of DKA associated with L-asp therapy reported in the literature

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Age (yr)/Sex</th>
<th>Diagnosis</th>
<th>Symptoms and signs</th>
<th>Onset after the last dose of L-asp (days)</th>
<th>Associated clinical manifestation</th>
<th>Therapy</th>
<th>Long-term sequelae</th>
<th>Outcome</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>12/F</td>
<td>ALL</td>
<td>Nausea, vomiting, polyuria, polydipsia, vaginal pruritus</td>
<td>20</td>
<td>Oral and vaginal candidiasis</td>
<td>Insulin and supportive treatment</td>
<td>Nil</td>
<td>CR</td>
<td>13</td>
</tr>
<tr>
<td>2</td>
<td>56/M</td>
<td>ALL</td>
<td>Cardiopulmonary embarrassment</td>
<td>11</td>
<td>Acute hemorrhagic pancreatitis</td>
<td>Supportive resuscitation</td>
<td>Nil</td>
<td>Died</td>
<td>6</td>
</tr>
<tr>
<td>3</td>
<td>30/M</td>
<td>ALL</td>
<td>Vomiting, diarrhea, dyspnea, oliguria</td>
<td>1</td>
<td>Pneumonia</td>
<td>Insulin, supportive resuscitation, antibiotics</td>
<td>Nil</td>
<td>Died</td>
<td>8</td>
</tr>
<tr>
<td>4</td>
<td>10.5/F</td>
<td>ALL</td>
<td>Lethargy, irritable, polydipsia, polyuria, Kussmaul respiration</td>
<td>2</td>
<td>Nil</td>
<td>Insulin and supportive treatment</td>
<td>Persistent hyperglycemia, ketouria</td>
<td>Died</td>
<td>10</td>
</tr>
<tr>
<td>5</td>
<td>10/F</td>
<td>AL</td>
<td>Lethargy, irritable, polydipsia, polyuria, Kussmaul respiration</td>
<td>2</td>
<td>Small abscess on the right upper eyelid</td>
<td>Insulin, supportive resuscitation, antibiotics</td>
<td>Nil</td>
<td>CR</td>
<td>3</td>
</tr>
<tr>
<td>6</td>
<td>13/M</td>
<td>AL</td>
<td>Polyuria</td>
<td>5</td>
<td>Neutropenia, small rectal fissure</td>
<td>Insulin, supportive treatment, antibiotics</td>
<td>Nil</td>
<td>CR</td>
<td>14</td>
</tr>
<tr>
<td>7</td>
<td>9/M</td>
<td>ALL</td>
<td>NS</td>
<td>NS</td>
<td>Pancreatitiis, secondary peritonitis</td>
<td>Insulin, supportive treatment, antibiotics</td>
<td>NS</td>
<td>NS</td>
<td>2</td>
</tr>
<tr>
<td>8</td>
<td>11/F</td>
<td>ALL</td>
<td>NS</td>
<td>NS</td>
<td>Nil</td>
<td>Insulin and supportive treatment</td>
<td>NS</td>
<td>NS</td>
<td>2</td>
</tr>
<tr>
<td>9</td>
<td>NS</td>
<td>AL</td>
<td>NS</td>
<td>4</td>
<td>Nil</td>
<td>NS</td>
<td>NS</td>
<td>Died</td>
<td>1</td>
</tr>
<tr>
<td>10</td>
<td>NS</td>
<td>AL</td>
<td>NS</td>
<td>NS</td>
<td>Nil</td>
<td>NS</td>
<td>NS</td>
<td>Alive</td>
<td>1</td>
</tr>
<tr>
<td>11</td>
<td>10/M</td>
<td>ALL</td>
<td>Nausea, vomiting, abdominal pain, conscious change</td>
<td>Days and 2 weeks</td>
<td>Acute pancreatitis, perianal abscess</td>
<td>Insulin, supportive treatment, antibiotics</td>
<td>Nil</td>
<td>CR</td>
<td>11</td>
</tr>
<tr>
<td>12</td>
<td>21/M</td>
<td>ALL</td>
<td>Epigastric pain, nausea, Vomiting</td>
<td>6 weeks and 10 months</td>
<td>Pancreatitiis, pseudocyst formation</td>
<td>Insulin, supportive treatment, antibiotics</td>
<td>Persistent diabetes, recurred DKA</td>
<td>CR</td>
<td>This case</td>
</tr>
</tbody>
</table>

ALL = acute lymphoblastic leukemia; CR = complete remission; AL = acute leukemia; NS = not stated.
References